AR and breast carcinoma: In fact, although the luminal androgen receptor subtype of breast cancer was the focus of these studies, AR is known to be more highly expressed in ER-positive breast cancers, including luminal B subtype cancers, and may represent a novel and effective treatment opportunity in these patients.